Exercise Rehabilitation for Critical Limb Ischemia Patients After Revascularization: Pilot Randomized Controlled Trial Assessing Functional Capacity and Quality of Life After a 12-week Rehabilitation Program Versus Best Medical Therapy
Phase: NA
Conditions: Peripheral Arterial Disease, Critical Limb Ischemia
Sponsor: University of Calgary

 
TITLE: Exercise rehabilitation for patients with critical limb ischemia peripheral arterial disease after 
revascularization: a single center pilot randomized controlled trial assessing quality of life and functional 
capacity after a 12-week rehabilitation program compared with best medical therapy  
BACKGROUND 
Definitions 
Peripheral arterial disease (PAD) refers to narrowing and occlusion of arteries supplying oxygenated 
blood to non-coronary and non-intracranial circulatory systems. This term is typically used to describe 
disease in the legs though it also affects upper extremities, renal and mesenteric vessels (Hiatt et al., 
2008). Atherosclerosis is a key cause of PAD and is the main focus of this particular study. Other more 
rare conditions that can lead to PAD include anatomical/congenital variation, fibromuscular dysplasia 
(FMD), vasculitides, trauma and localized radiation (Gerhard-Herman et al., 2017; Hirsch et al., 2006).  
PAD patients present with a wide range of symptoms. Patients who are non-ambulatory or with 
subclinical levels of disease may be asymptomatic and unaware of the disease process. Symptomatic 
patients typically experience leg pain with walking or physical activity, which is referred to as 
intermittent claudication (IC) (Dormandy & Rutherford, 2000; Hiatt et al., 2008; Norgren et al., 2007).  In 
more advanced chronic disease states with severely compromised blood flow to the tissues, patients 
may have leg pain at rest or even non healing wounds that can lead to tissue loss which is defined as 
critical limb ischemia (CLI) (Hiatt et al., 2008; Hirsch et al., 2006; Varu, Hogg, & Kibbe, 2010). These 
clinical presentations have led to the development of two main classification systems that describe the 
severity of PAD; the Fontaine classification and Rutherford classification (Table 1.)  
Fontaine 
Rutherford 
Stage 
Clinical presentation 
Grade 
Category 
Clinical presentation 
I 
Asymptomatic 
0 
0 
Asymptomatic 
II 
Mild claudication 
I 
1 
Mild claudication 
IIb 
Moderate to severe 
claudication 
I 
2 
Moderate claudication 
I 
3 
Severe claudication 
III 
Ischemic rest pain 
II 
4 
Ischemic rest pain 
IV 
Ulceration or gangrene 
III 
5 
Minor tissue loss 
III 
6 
Major tissue loss 
 
Patients with intermittent claudication typically experience leg pain associated with walking or other 
physical activity which is relieved with a short period of rest. Pain may be present in calves, thighs 
and/or buttocks depending on the anatomical level of disease (Criqui & Aboyans, 2015; Gerhard-
Herman et al., 2017). Validated questionnaires can be used as a diagnostic tool to rule out other causes 
of the patient’s symptoms (Criqui et al., 1996; Leng & Fowkes, 1992; Rose, 1962). It is important to note 
that symptoms can be highly variable in severity depending on level of activity.  
Table 1. Fontaine and Rutherford classification of PAD (Dormandy & Rutherford, 2000) 

The ankle brachial index (ABI) should be used an initial assessment for the confirmation of the presence 
and severity of PAD (Gerhard-Herman et al., 2017; Norgren et al., 2007; Schroder et al., 2006). ABI is a 
ratio of systolic blood pressure in the brachial artery to the highest measured blood pressure at the 
ankle. This test has been shown to be highly specific but not sensitive to the presence of PAD (Khan, 
Farooqui, & Niazi, 2008; Lijmer, Hunink, van den Dungen, Loonstra, & Smit, 1996). An ABI of <0.9 is 
indicative of PAD and values <0.4 are used as a threshold for CLI. For ABI values >1.3, the vessels are 
deemed non-compressible and further evaluation is required. (Gerhard-Herman et al., 2017; Hirsch et 
al., 2006; Khan et al., 2008). In these patients with non-compressible vessels or CLI, it is appropriate to 
obtain a toe-brachial index (Gerhard-Herman et al., 2017). 
In patients with severe symptoms and who may require revascularization, diagnostic imaging is 
required. Imaging techniques for anatomic assessment include duplex ultrasound (DUS), computed 
tomography angiography (CTA), magnetic resonance angiography (MRA) or direct conventional 
angiography (Gerhard-Herman et al., 2017; Norgren et al., 2007). These diagnostic tests can be costly, 
time intensive, invasive, and may expose patients to risks, particularly when iodinated contrast is used.  
This is why it is important to have a thorough clinical assessment and management plan for these 
patients.  
Epidemiology 
A recent systematic review reports a global estimate of 202 million people living with PAD as of 2010 
(Fowkes et al., 2013). Previously thought to be predominant in high income countries, this systematic 
review suggests that almost 70% of people suffering from PAD reside in lower and middle income 
countries. This systematic review compared global prevalence of PAD between 2000 and 2010 which 
showed a global increase in PAD of approximately 23.5%.  The data show that PAD generally affects men 
and women at similar rates, with a slightly higher prevalence in women at older ages. This differs from 
previous works that suggested higher rates among men than women. The prevalence of PAD increases 
with increasing patient age, with a sharp rise in numbers ≥70 years of age (Criqui & Aboyans, 2015).  
An elegant and powerful comment written by Hirsch and Duval (2013) describe PAD as a global 
pandemic given that it affects more than 200 million people worldwide. PAD greatly affects people’s 
quality of life with a high degree of morbidity and mortality making this an important and relevant area 
of research. To put in context, as of 2011 approximately 34 million people were living with HIV. By 
comparison, PAD has a higher prevalence, morbidity and mortality compared with HIV (Hirsch & Duval, 
2013). 
Patients with CLI are the focus of this study. Although the incidence is clear, it is estimated that in 
Europe and North America there are 500-1000/1 million new cases of CLI every year. These patients 
exhibit the most severe form of the disease with guarded prognoses. At one year, there is a 10-40% 
mortality rate and up to 40% amputation rate in patients with critical limb ischemia.  Only 45% of 
patients are alive with two limbs one year after a diagnosis of CLI (Hirsch et al., 2006; Norgren et al., 
2007). These patients tend to be in extremely poor health with multiple comorbidities that are further 
outlined below. 

Risk Factors 
Patients with PAD typically have numerous risk factors that contribute directly to their atherosclerotic 
disease. These risk factors are commonly shared with other cardiovascular diseases. The key risk factors 
include smoking, diabetes, hypertension and dyslipidemia. Smoking is the number one risk factor linked 
to PAD, and has been shown to be a higher risk factor for PAD compared with other CV diseases (Cole et 
al., 1993; Norgren et al., 2007) (Agarwal, 2009). Current smokers have the highest risk for PAD, though 
any history of smoking does increase chances of getting the disease (Cole et al., 1993; Willigendael et al., 
2004). There is also a strong association between diabetes and PAD. Specifically, the longer the duration 
of the disease, the higher the risk of developing PAD (Hirsch et al., 2006; Norgren et al., 2007).  
Furthermore, patients with diabetes have worse outcomes than those without, with higher rates of 
amputation and cardiovascular death (da Silva et al., 1996; Takahara et al., 2010). Systolic hypertension 
is a significant risk factor for PAD. The relative risk is only moderate with hypertension but given its 
ubiquitous presence in an aging population, it is highly relevant in assessment of patients with PAD 
(Bavry et al., 2010). Increased total cholesterol and low high-density lipoproprotein (HDL) HDL have 
been shown to be independent risk factors in patients with PAD. Finally, there are several blood markers 
that have been linked to PAD including hyperhomocysteinemia, elevated C-reactive protein (CRP) and 
elevated fibrinogen (Norgren et al., 2007).   
Patients with PAD typically have coexisting cardiovascular diseases as expected given the common risk 
factors outlined above. These patients are at significantly higher risk for angina, myocardial infarct (MI), 
congestive heart failure, stroke and TIA. Therefor it is crucial to ensure that risk factors are addressed 
and modified in this PAD population for improved functional status and longevity (Norgren et al., 2007).  
Risk factor management 
Risk factor management is critical for PAD patients with the goal of improving symptoms and preventing 
disease progression. Smoking cessation should be a primary focus. Patients who smoke should be 
repeatedly encouraged to quit by providing tools such as counselling and suitable pharmacotherapy. 
Hypertension control should be initiated with blood pressure targets of 140/90 or 130/80 for patients 
with diabetes. First line agents include angiotensin converting enzyme inhibitors (ACEi) or angiotensin 
receptor blockers (ARB). Calcium channel blockers and beta-blockers are also appropriate for use in this 
population. Dyslipidemia needs to be controlled with efforts to decrease LDL-C to < 2.0 mmol/L with 
statins as first line agents.  Diabetic patients should optimize blood glucose level with a target HbA1C of 
<7%. Antiplatelet therapy should be initiated in symptomatic patient or when other risk factors are 
present. Dual anti-platelet regimes are particularly helpful for patients with PAD.  Exercise interventions 
should be encouraged in all patients with PAD. Given that exercise is the focus of this research, it is 
described in greater detail below (Gerhard-Herman et al., 2017; Hirsch et al., 2006; Norgren et al., 
2007).  
Revascularization  
In patients who have progressed to critical limb ischemia, treatment goals are to relieve pain, heal 
wounds and prevent limb loss. In addition to risk factor management and medical therapy, these 

patients require revascularization procedures. Depending on the extent and location of disease, the 
techniques used may be endovascular/interventional, surgical or hybrid-based (Varu et al., 2010).   
Limb salvage rates are thought to be similar with both endovascular and open techniques, however the 
data are limited and there is a large ongoing randomized controlled trial addressing this issue (Adam et 
al., 2005; Albers, Romiti, Brochado-Neto, De Luccia, & Pereira, 2006; Romiti et al., 2008). Endovascular 
techniques offer a less invasive option with typically only one or two small (≤5mm) groin incisions to 
access the affected vessels.  It also has an advantage of lower morbidity and with open bypass 
procedures (Adam et al., 2005). Endovascular options typically require iodinated contrast, which may 
expose the patients to a risk of kidney injury, which is not uncommon in this population given their 
comorbidities, and in particular a high frequency of diabetes. While open bypass procedures may be 
associated with higher wound complication rates, they have been shown to have better long-term 
patency compared with endovascular interventions (Romiti et al., 2008; Varu et al., 2010). 
Balloon angioplasty with and without stenting can be used to open narrowed or occluded vessels. In 
patients with longer lesions and more diffuse disease open surgical bypass techniques are typically used 
to provide revascularization to ischemic limbs (Gerhard-Herman et al., 2017; Hirsch et al., 2006; Norgren 
et al., 2007). In some cases, a hybrid approach is used with a combination of balloon angioplasty, 
stenting and surgical bypass. In cases where there are no revascularization options, patients may require 
a primary amputation of their limbs to manage pain and/or infection (Gerhard-Herman et al., 2017; Varu 
et al., 2010). 
It is important to note that in Canada, and specifically in Calgary, revascularization is reserved with 
patients who have critical limb ischemia or severely life-limiting claudication. Many institutions do offer 
revascularization (typically endovascular) for patients who have IC. This is relevant given that patients 
with CLI have end-stage disease as noted previously, and typically have a significantly greater number of 
comorbidities.  
Outcomes after revascularization 
Patency and limb salvage are the primary measures for revascularization success in CLI patients.  
Primary and secondary patency rates at one year are significantly lower with endovascular compared 
with open surgical techniques, while limb salvage rates are similar in both groups (Romiti et al., 2008). 
Table 2. shows results from a meta-analysis comparing endovascular versus open bypass outcomes in 
patients with CLI. While limb salvage rates are similar, this analysis does not capture the frequency of re-
interventions for either modality.  Conte et al. (2009) showed in a meta-analysis of infra-inguinal surgical 
bypass procedures that only 61% of patients remain free from any amputation or re-intervention at one 
year. That number is significantly higher in the endovascular group (Conte et al., 2009).   
It is important to note that limb salvage rates always surpass patency rates regardless of treatment 
modality. This is because revascularization allows patients to heal ischemic wounds and hopefully 
increase ambulation which will assist with collateral vessel development. 

 
Exercise and Peripheral arterial disease  
There has been a tremendous amount of research showing the advantages of exercise training for 
patients with IC (Aggarwal et al., 2016). Supervised exercise programs (SEP) are recommended as a first 
line of treatment for patients with PAD (Milani & Lavie, 2007; Murphy et al., 2012). In patients with IC, 
supervised exercise programs have been shown to have superior results compared with endovascular 
revascularization with respect to functional capacity (Murphy et al., 2012; Perkins, Collin, Creasy, 
Fletcher, & Morris, 1996; Spronk et al., 2009). Unfortunately, once a patient has reached the most 
severe stage of PAD in the form of CLI, exercise is no longer an appropriate initial treatment modality 
and they typically require some surgical or endovascular intervention. For patients with IC who do not 
have access to SEP, a home exercise program (HEP) may be a viable alternative (Aggarwal et al., 2016; 
Gardner, Parker, Montgomery, Scott, & Blevins, 2011; McDermott et al., 2009). SEP and HEP both 
increase maximal walking distance, functional capacity and quality of life in patients with IC, with 
outcomes slightly favoring SEP.   
 
Exercise Modality 
Walking is the most common modality of exercise prescribed and studied in patients with IC which may 
be a challenge in patients who have difficulty ambulating. There are a limited number of studies that 
have used alternative training strategies with variable outcomes (Parmenter, Dieberg, & Smart, 2015; 
Parmenter, Raymond, Dinnen, Lusby, & Fiatarone Singh, 2013). Both arm and leg cycle-ergometry have 
been shown to be viable exercise modalities for patients with IC, and can improve maximal walking 
distance (MWD) (Zwierska et al., 2005).  A recent study also showed that calf-raises done 3 times per 
day for eight weeks can cause greater improvements in MWD compared with patients who completed a 
more traditional walking training program (Van Schaardenburgh, Wohlwend, Rognmo, & Mattsson, 
2017). Most of the studies employing exercise modalities other than walking typically include a small 
number of subjects, with limited positive outcomes. These alternative exercise modalities are arguably 
Table 2. Meta-analysis of 1-month to 3-year patency, limb salvage, and patient survival (%) in patients 
with critical limb ischemia comparing percutaneous transluminal angioplasty vs bypass grafting 
Result 
1 month 
6 months 
1 year 
2 years 
3 years 
Primary patency 
 
 
 
 
 
 PTA 
77.4 ± 4.1 
65.0 ± 7.0 
58.1 ± 4.6 
51.3 ± 6.6 
48.6 ± 8.0 
 Bypass 
93.3 ± 1.1 
85.8 ± 2.1 
81.5 ± 2.0 
76.8 ± 2.3 
72.3 ± 2.7 
 P 
<.05 
<.05 
<.05 
<.05 
<.05 
Secondary patency 
 
 
 
 
 
 PTA 
83.3 ± 1.4 
73.8 ± 7.1 
68.2 ± 5.9 
63.5 ± 8.1 
62.9 ± 11.0 
 Bypass 
94.9 ± 1.0 
89.3 ± 1.6 
85.9 ± 1.9 
81.6 ± 2.3 
76.7 ± 2.9 
 P 
<.05 
<.05 
<.05 
 
 
Limb salvage 
 
 
 
 
 
 PTA 
93.4 ± 2.3 
88.2 ± 4.4 
86.0 ± 2.7 
83.8 ± 3.3 
82.4 ± 3.4 
 Bypass 
95.1 ± 1.2 
90.9 ± 1.9 
88.5 ± 2.2 
85.2 ± 2.5 
82.3 ± 3.0 
Patient survival 
 
 
 
 
 
 PTA 
98.3 ± 0.7 
92.3 ± 5.5 
87.0 ± 2.1 
74.3 ± 3.7 
68.4 ± 5.5 
 Bypass 
NA 
NA 
NA 
NA 
NA 

more important and applicable to patients with PAD, particularly those with more severe symptoms as 
these patients will have the greatest mobility challenges as a limiting factor in exercise participation. 
Resistance training has shown to be beneficial in PAD patients but is rarely emphasized as a treatment 
modality. Furthermore, alternative activities such as yoga, pilates or aquatic exercise have not been 
investigated in this patient population and may have benefits that have not yet been elucidated.  
 
Exercise Training Post-Revascularization 
Only a small number of studies have evaluated SEP after revascularization.  Four RCTs have compared 
patients who have undergone revascularization for intermittent claudication via endovascular approach 
and were subsequently enrolled in exercise programs versus best medical therapy (Bo et al., 2013; 
Greenhalgh et al., 2008; Kruidenier et al., 2011; Mazari et al., 2010).  All of these studies showed 
significant improvements in walking distance and quality of life for patients enrolled in the exercise 
programs. There are three RCTs comparing exercise versus BMT in post peripheral bypass surgery which 
showed similar results of significantly increased walking distance and QoL in the post-op exercise group 
(Badger, Soong, O'Donnell, Boreham, & McGuigan, 2007; Jakubseviciene et al., 2014; Lundgren, Dahllof, 
Lundholm, Schersten, & Volkmann, 1989). Out of all of these studies, only Badger et. al (2007) showed 
an improvement in ABI in patients who had undergone bypass surgery for revascularization and 
participated in a post-operative exercise program versus bypass surgery and BMT alone.  Jakubseviciene 
et. al (2014) and Lundgren et al (1989) had patients participating in HEP, which also showed significantly 
better walking distances and QoL compared with the BMT groups. Currently, there are no studies 
evaluating the efficacy of HEP alone compared to SEP after revascularization. 
 
All of the studies described here were primarily treating patients with IC. Only Jakubsvieciene et al. 
(2014) and Badger et al (2007) included patients with PAD and rest pain.  To date, there are no studies 
dedicated to patients with critical limb ischemia comparing outcomes for exercise training versus BMT 
post revascularization.  All of these studies exclusively evaluate patient-related outcomes such as 
walking distance, functional capacity and QoL. While these parameters are tremendously important, 
there are no data regarding how post treatment exercise training may affect amputation rates, 
readmission to hospital or reintervention rates in the PAD patients with critical limb ischemia. Such 
parameters are defined as major adverse limb events (MALE). 
  
Health Economics 
The 1992 Canadian Heart Health survey showed a significant economic benefit for all participants who 
participated in an exercise program, both supervised and unsupervised. In patients with known 
cardiovascular disease, a SEP showed significant cost savings for years of life (Lowensteyn, Coupal, 
Zowall, & Grover, 2000). In patients with IC, studies have shown that SEP is more cost- effective than 
endovascular interventions as a primary treatment modality. Furthermore, although the initial cost of 
SEP may be slightly greater when compared with HEP, it has greater cost-effectiveness up to five years 
(Fokkenrood et al., 2014; Reynolds et al., 2014; Spronk et al., 2009). There has been no data evaluating 
the cost benefits associated with CLI patients who have undergone revascularization. Given that re-
interventions are frequent (and costly), post revascularization exercise training may be of significant and 
substantial benefit in patients with CLI.  

 
Summary 
Exercise training is a proven effective treatment for patients with PAD with significant functional, 
psychosocial and economic benefits. In current practice, there are no guidelines for exercise training and 
rehabilitation for patients who have progressed to CLI and have undergone revascularization.  While it 
may be a challenge given the severity of disease and number of comorbidities in this patient population, 
it is great a disservice to deny these patients exercise rehabilitation given the possible advantages for 
their functional capacity, quality of life and even survival. Randomized controlled trials (RCT) are 
necessary to determine the precise role of exercise rehabilitation in patients with CLI. An RCT will 
provide guidance for regarding exercise tolerance, appropriate exercise modalities as well as the 
challenges and benefits of exercise rehabilitation in this critically ill population. 
Objectives: 
The aim of this pilot study is to develop a better understanding of the role for supervised exercise 
rehabilitation programs (SEP) in CLI patients after revascularization.  
 
Our key objectives are as follows: 
1) Our primary objective is to show that a 12-week SEP will improve functional capacity and quality of 
life in patients with CLI after revascularization. We will assess the feasibility for completion of a 12-week 
SEP in patients with CLI who have undergone revascularization. 
2) Our secondary objective is to monitor major adverse limb events (MALE) and survival in patients who 
complete a 12-week SEP after revascularization. 
 
Hypotheses: 
1) We hypothesize that PAD-CLI patients who participate in an exercise rehabilitation after they have 
undergone revascularization will have a greater improvement in functional capacity and quality of life 
compared with patients treated with best medical therapy alone.  
2) We hypothesize that PAD-CLI patients who participate in an exercise rehabilitation after they have 
undergone revascularization will have fewer MALE and improved survival compared with patients 
treated with best medical therapy alone.  
 
OUTCOME MEASURES: 
 
Primary outcome measures: 
Our primary outcome measure for this project will be change in functional capacity as measured by a 6-
minute walking test (6MWT) or maximal pain-free walking distance on a treadmill. 
 
Secondary outcome measures: 
1) Quality of life based on questionnaires validated for patients with PAD, the SF-36 and VQ6 
2) Completion of a 12 week supervised exercise program 
2) Freedom from MALE 
3) Target vessel and/or bypass patency 
4) Survival at 1, 3 and 5 years 
 
STUDY DESIGN 
 

This study is a two phase, single-center, non-blinded randomized controlled trial. The first phase of the 
trial will include 20 patients; 10 assigned to post-operative exercise rehabilitation and 10 to best medical 
therapy.  The primary objective of Phase I is to assess for feasibility and safety of this randomized 
controlled trial in CLI patients after revascularization.  We will assess rate of enrollment, adherence to 
the exercise regimen and any unforeseen barriers or challenges that patients may encounter with the 
rehabilitation program. 
 
If Phase I of the trial confirms that the exercise program is feasible and safe for CLI patients post-
revascularization, we will proceed with Phase II of the trial. The primary objective for Phase II is to 
determine if a supervised exercise rehabilitation program will improve walking distance after 
revascularization comparted with patients treated with best medical therapy.  Phase II will also compare 
quality of life outcomes between the two groups.  
 
STUDY POPULATION 
The population to be studied in this group is patients with PAD and CLI Fontaine classification III and IV. 
This means that these patients will have ischemic rest pain in their legs and/or non-healing ischemic 
ulcers on their feet.  
 
ENROLLMENT 
Patients will be identified on a referral basis through our outpatient vascular surgery clinic.  The seven 
practicing vascular surgeons in Calgary will be informed of the current study. Patients who have 
undergone revascularization for CLI will be identified for consideration of participation in this study 
within six months of their procedure.  All surgical and ischemic wounds to be deemed sufficiently healed 
prior to assessment for fitness in the study. Once the attending vascular surgeon considers the patient 
fit to participate, the research coordinator will assess the patient for possible inclusion in the study.   
 
Inclusion Criteria 
1) Ambulating prior to procedure 
2) Living independently prior to procedure 
3) Available to attend all SEP and follow-up appointments  
4) PAD Fontaine class III and IV (rest pain and tissue loss)  
5) Entry with consent of vascular surgeon 
6) Ischemia secondary to TASC A-D lesions identified on imaging (CTA or angiogram) 
7) Able to understand and sign informed consent  
8) >18 years of age 
 
Exclusion Criteria 
1) Confined to wheelchair 
2) Patients with exercise tolerance limitations due to other co-morbidities such as 
cardiorespiratory, musculoskeletal, or peripheral neuropathy.  (NYHA class III and IV) 
3) PAD Fontaine class I and II (asymptomatic, claudication) 
4) Patients with ongoing tissue loss that limits ambulation 
5) Patient with previous revascularization procedures 
6) Patients undergoing revascularization for acute limb ischemia events 
 
SAMPLE SIZE 
There are currently no data evaluating outcomes of post-revascularization supervised exercise programs 
in patients with critical limb ischemia, however these studies have been completed in claudication 

patients.  Studies on PAD claudication (Fontaine class II) patients who have undergone revascularization 
followed by SEP have all shown significant improvement in functional capacity compared with best 
medical therapy alone. These previous studies that showed consistently a 20% greater increase in 
walking distance in the post-revascularization SEP group compared with Best Medical Therapy (BMT) 
post-revascularization. Given this previous data, 64 patients are required to have a 80% chance of 
detecting, with a two-sided significance of 0.05, an increase in the primary outcome measure of a 20% 
greater increase in distance for the 6MWT in the experimental group comparted with the control group. 
Final sample size will be adjusted for expected attrition. 
 
METHODS 
INTERVENTION 
Patients included in the study will be identified in the vascular surgery outpatient clinic or through 
Emergency department as requiring revascularization secondary to critical limb ischemia.  Patients will 
be approached regarding study participation prior to the revascularization procedure.   After eligibility is 
confirmed and patients have signed informed consent, patients will be randomized to one of two 
groups: 
1) Best Medical Therapy (BMT) 
2) BMT + Supervised Exercise Program (SEP) 
 
The patient will undergo the revascularization procedure and any adjunctive treatment such as wound 
care/debridement or minor amputation (toes, trans-metatarsal amputation).  All surgical wounds and 
ischemic ulcers will require assessment by attending surgeon for adequate healing prior to initial 
assessment at the exercise facility.  This may require as little as one week or as long as 6 weeks to 
achieve sufficient healing.  The exercise assessment and program delivery will take place at a cardiac 
rehabilitation facility that has extensive experience in managing patients with cardiovascular disease 
and PAD in the post op setting.  
 
Best medical therapy  
All patients in the study will be assessed and monitored by internal medicine specialists as well as the 
vascular surgery team for management of PAD risk factors including, but not limited to: hypertension, 
smoking cessation, dyslipidemia and diabetes. The patients will be prescribed appropriate 
pharmacotherapy as deemed appropriate.  A typical regimen for these patients may include antiplatelet 
agents, B-blockers, ACE-inhibitors, and diabetic control agents. Patients will be advised to target a 
systolic blood pressure of ≤140mmHg (≤130mmHg if diabetic), LDL-C < 2.0 mmol/L and a HbA1c ≤7%.  
They will also be given information regarding engaging in exercise and physical activity three to five 
times per week. Patients will be asked to keep a log of their physical activity for the 12-week duration of 
the study. The patients will be provided with a log to record their physical activity. 
 
Standardized Exercise Program Regimen 
In addition to best medical therapy management, the patients randomized to the SEP arm of the trial 
will attend a supervised exercise program at a cardiac rehabilitation facility at least two times per week 
for 12 weeks. Programs will be designed and coordinated by an exercise physiologist. All patient 
expenses for the program will be covered by the study budget. There will be no financial burden placed 
on the participants.  
 
MEASUREMENTS 
General health metrics will be collected at the start and end of the 12-week intervention period. This 
includes height, weight, BMI, blood pressure and resting heart rate.  We will record medications, 

smoking history status, presence of diabetes, dyslipidemia, cardiovascular disease history including 
previous myocardial infarct (MI) and stroke/transient ischemic attack. 
 
PRE/POST TESTING 
Functional Capacity: 
In order to assess functional capacity, we will measure walking performances at the first exercise session 
and after 12 weeks. Walking performance will be measured using a six-minute walk test (6MWT) (Guyatt 
et al, 1985) which has been validated in the functional evaluation of chronic disabling disease, more 
specifically in patients with PAD (Gardner, Montgomery, & Parker, 2012; McDermott et al., 2009). For 
this test, the patients will be made to walk on a flat surface for 6 minutes and total distance covered will 
be recorded by the test administrator. Patients will also undergo a graded treadmill test to evaluate 
maximum walking distance (MWD) and pain-free walking distance (PFWD).  The treadmill is set at a 
constant speed of 3.2km/hr and starts at an incline of 0%, increasing by 2% every 2 minutes until an 
incline of 10% is reached or the patients stops the test (Gardner et al., 2012). This test is also commonly 
used and has been validated in PAD patients. 
 
Quality of Life (QoL): 
Validated generic and PAD-specific QoL questionnaires will be administered at the first and final visits. 
The Short Form 36 (SF-36) and VascuQol.  The SF-36 is a generic health status questionnaire, while the 
VascuQol is a quality of life questionnaire validated for patients with PAD.  
 
Given that this is a pilot study to assess the feasibility in exercise rehabilitation in this population that is 
considered end-stage PAD, we want to capture major challenges or barriers for these patients. As such, 
we will also perform an interview and survey at the mid-term and at the completion of exercise program 
for the SEP group to collect information around challenges associated with the rehabilitation. 
 
Limb Hemodynamics: 
Ankle brachial index (ABI) measurements will be recorded at initial assessment and 12 weeks as a 
measure of peripheral arterial blood flow.  ABI is obtained by measuring the highest systolic pressure at 
the ankle over the highest systolic pressure in the arm. We will use a handheld Doppler probe and blood 
pressure cuff to collect these measurements. We will also use duplex arterial ultrasound at 2 weeks post 
intervention and again at 12 weeks to monitor patency of revascularization.  
 
RANDOMIZATION 
Microsoft Excel will be used to generate a block randomization sequence for Phase I (20 patients) 
followed by a block randomization sequence for Phase II (44 patients) of the study.  Patients who are 
eligible to participate in the study will be stratified by sex and randomized to either SEP or BMT.  Block 
sizes of 4 and 6 will be used to prevent anticipation of the randomization sequence.   
 
ALLOCATION CONCEALMENT 
Once the random block sequence has been generated, allocation cards will be created and sealed in 
sequentially numbered opaque envelopes. The envelopes will be stored in a secured filing cabinet in the 
vascular surgery research office. The envelopes will be opened sequentially after a patient consents to 
participate in the study. 
 
DATA COLLECTION 
No study data will be collected until patients have reviewed and signed the informed consent.  
Opportunity to ask questions and have time independent from study team will be provided. 

Data will be recorded using Excel spreadsheets. Medical outcomes and complications will be tracked 
using Vascubase software. Data will be stored on Alberta Health Services computers to maintain patient 
confidentiality. 
 
STATISTICAL ANALYSIS 
Normally distributed data will be presented as mean ± SD. Results at baseline and 12 weeks will be 
compared using a paired t-test. For data that is not normally distributed, comparisons will be performed 
using a non-parametric Mann-Whitney test. Comparisons will be accepted as statistically significant at 
95% confidence level (p≤0.05). STATA software will be used for statistical analysis. 
 
ETHICAL CONSIDERATIONS 
Patients who are randomized to the SEP group will be provided with tri-weekly visits for supervised 
exercise guidance and support. Patients will receive reimbursement for travel to and from the exercise 
facility. This will include refunds for gas, parking or other required transportation (taxi, public transport, 
etc).  
 
FOLLOW UP OF PATIENTS WITHDRAWN FROM STUDY 
Patients who withdraw or do not complete the program will be contacted and interviewed at the end of 
the 12 week study period to understand why they were unable to complete the training program.  
 
LIMITATIONS 
One expected limitation of this study is the heterogeneity of the revascularization approach. Some 
patients will undergo endovascular treatment, while others will receive an open surgical bypass. 
Additionally, patients will not be stratified according to anatomical level of disease (aorto-iliac versus 
infrainguinal disease).   
 
LONG-TERM FOLLOW-UP 
This project is a pilot project with 12-week primary endpoint measures of functional capacity and quality 
of life. Given that we plan to extend to a broader randomized controlled clinical trial with long term 
follow-up, we will continue to follow the patients annually for five years. The annual follow-up will 
include QoL surveys, ABI measurements, ultrasound assessment for graft patency and any MALE. We 
will also monitor survival throughout this period.  
 
 
 
 
 
 
 
 
REFERENCES 

 
Adam, D. J., Beard, J. D., Cleveland, T., Bell, J., Bradbury, A. W., Forbes, J. F., . . . Storkey, H. (2005). 
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised 
controlled trial. Lancet, 366(9501), 1925-1934. doi:10.1016/s0140-6736(05)67704-5 
Agarwal, S. (2009). The association of active and passive smoking with peripheral arterial disease: results 
from NHANES 1999-2004. Angiology, 60(3), 335-345. doi:10.1177/0003319708330526 
Aggarwal, S., Moore, R. D., Arena, R., Marra, B., McBride, A., Lamb, B., . . . Stone, J. (2016). Rehabilitation 
Therapy in Peripheral Arterial Disease. Can J Cardiol, 32(10s2), S374-s381. 
doi:10.1016/j.cjca.2016.07.509 
Albers, M., Romiti, M., Brochado-Neto, F. C., De Luccia, N., & Pereira, C. A. (2006). Meta-analysis of 
popliteal-to-distal vein bypass grafts for critical ischemia. J Vasc Surg, 43(3), 498-503. 
doi:10.1016/j.jvs.2005.11.025 
Badger, S. A., Soong, C. V., O'Donnell, M. E., Boreham, C. A., & McGuigan, K. E. (2007). Benefits of a 
supervised exercise program after lower limb bypass surgery. Vasc Endovascular Surg, 41(1), 27-
32. doi:10.1177/1538574406296209 
Bavry, A. A., Anderson, R. D., Gong, Y., Denardo, S. J., Cooper-Dehoff, R. M., Handberg, E. M., & Pepine, 
C. J. (2010). Outcomes Among hypertensive patients with concomitant peripheral and coronary 
artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension, 
55(1), 48-53. doi:10.1161/hypertensionaha.109.142240 
Bo, E., Hisdal, J., Cvancarova, M., Stranden, E., Jorgensen, J. J., Sandbaek, G., . . . Bergland, A. (2013). 
Twelve-months follow-up of supervised exercise after percutaneous transluminal angioplasty for 
intermittent claudication: a randomised clinical trial. Int J Environ Res Public Health, 10(11), 
5998-6014. doi:10.3390/ijerph10115998 
Cole, C. W., Hill, G. B., Farzad, E., Bouchard, A., Moher, D., Rody, K., & Shea, B. (1993). Cigarette smoking 
and peripheral arterial occlusive disease. Surgery, 114(4), 753-756; discussion 756-757.  
Conte, M. S., Geraghty, P. J., Bradbury, A. W., Hevelone, N. D., Lipsitz, S. R., Moneta, G. L., . . . Sidawy, A. 
N. (2009). Suggested objective performance goals and clinical trial design for evaluating 
catheter-based treatment of critical limb ischemia. J Vasc Surg, 50(6), 1462-1473.e1461-1463. 
doi:10.1016/j.jvs.2009.09.044 
Criqui, M. H., & Aboyans, V. (2015). Epidemiology of peripheral artery disease. Circ Res, 116(9), 1509-
1526. doi:10.1161/circresaha.116.303849 
Criqui, M. H., Denenberg, J. O., Bird, C. E., Fronek, A., Klauber, M. R., & Langer, R. D. (1996). The 
correlation between symptoms and non-invasive test results in patients referred for peripheral 
arterial disease testing. Vasc Med, 1(1), 65-71. doi:10.1177/1358863x9600100112 
da Silva, A. F., Desgranges, P., Holdsworth, J., Harris, P. L., McCollum, P., Jones, S. M., . . . Callam, M. 
(1996). The management and outcome of critical limb ischaemia in diabetic patients: results of a 
national survey. Audit Committee of the Vascular Surgical Society of Great Britain and Ireland. 
Diabet Med, 13(8), 726-728. doi:10.1002/(sici)1096-9136(199608)13:8<726::aid-
dia145>3.0.co;2-p 
Dormandy, J. A., & Rutherford, R. B. (2000). Management of peripheral arterial disease (PAD). TASC 
Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg, 31(1 Pt 2), S1-s296.  
Farah, B. Q., Ritti-Dias, R. M., Cucato, G. G., Montgomery, P. S., & Gardner, A. W. (2016). Factors 
Associated with Sedentary Behavior in Patients with Intermittent Claudication. Eur J Vasc 
Endovasc Surg, 52(6), 809-814. doi:10.1016/j.ejvs.2016.07.082 
Fokkenrood, H. J., Scheltinga, M. R., Koelemay, M. J., Breek, J. C., Hasaart, F., Vahl, A. C., & Teijink, J. A. 
(2014). Significant savings with a stepped care model for treatment of patients with intermittent 
claudication. Eur J Vasc Endovasc Surg, 48(4), 423-429. doi:10.1016/j.ejvs.2014.04.020 

Fowkes, F. G., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J. O., McDermott, M. M., . . . Criqui, M. H. 
(2013). Comparison of global estimates of prevalence and risk factors for peripheral artery 
disease in 2000 and 2010: a systematic review and analysis. Lancet, 382(9901), 1329-1340. 
doi:10.1016/s0140-6736(13)61249-0 
Gardner, A. W., Montgomery, P. S., & Parker, D. E. (2012). Optimal exercise program length for patients 
with claudication. J Vasc Surg, 55(5), 1346-1354. doi:10.1016/j.jvs.2011.11.123 
Gardner, A. W., Parker, D. E., Montgomery, P. S., Scott, K. J., & Blevins, S. M. (2011). Efficacy of 
quantified home-based exercise and supervised exercise in patients with intermittent 
claudication: a randomized controlled trial. Circulation, 123(5), 491-498. 
doi:10.1161/circulationaha.110.963066 
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., . . . 
Walsh, M. E. (2017). 2016 AHA/ACC Guideline on the Management of Patients With Lower 
Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 
135(12), e686-e725. doi:10.1161/cir.0000000000000470 
Greenhalgh, R. M., Belch, J. J., Brown, L. C., Gaines, P. A., Gao, L., Reise, J. A., & Thompson, S. G. (2008). 
The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication 
(MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: 
results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. 
Eur J Vasc Endovasc Surg, 36(6), 680-688. doi:10.1016/j.ejvs.2008.10.007 
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. B. 
(1985). The 6-minute walk: a new measure of exercise capacity in patients with chronic heart 
failure. Can Med Assoc J, 132(8), 919-923.  
Hiatt, W. R., Goldstone, J., Smith, S. C., Jr., McDermott, M., Moneta, G., Oka, R., . . . Pearce, W. H. (2008). 
Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. 
Circulation, 118(25), 2826-2829. doi:10.1161/circulationaha.108.191171 
Hirsch, A. T., & Duval, S. (2013). The global pandemic of peripheral artery disease. Lancet, 382(9901), 
1312-1314. doi:10.1016/s0140-6736(13)61576-7 
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., . . . Riegel, B. (2006). 
ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial 
disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from 
the American Association for Vascular Surgery/Society for Vascular Surgery, Society for 
Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, 
Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing 
Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial 
Disease): endorsed by the American Association of Cardiovascular and Pulmonary 
Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; 
TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation, 113(11), 
e463-654. doi:10.1161/circulationaha.106.174526 
Jakubseviciene, E., Vasiliauskas, D., Velicka, L., Kubilius, R., Milinaviciene, E., & Vencloviene, J. (2014). 
Effectiveness of a new exercise program after lower limb arterial blood flow surgery in patients 
with peripheral arterial disease: a randomized clinical trial. Int J Environ Res Public Health, 11(8), 
7961-7976. doi:10.3390/ijerph110807961 
Khan, T. H., Farooqui, F. A., & Niazi, K. (2008). Critical review of the ankle brachial index. Curr Cardiol 
Rev, 4(2), 101-106. doi:10.2174/157340308784245810 
Kruidenier, L. M., Nicolai, S. P., Rouwet, E. V., Peters, R. J., Prins, M. H., & Teijink, J. A. (2011). Additional 
supervised exercise therapy after a percutaneous vascular intervention for peripheral arterial 

disease: a randomized clinical trial. J Vasc Interv Radiol, 22(7), 961-968. 
doi:10.1016/j.jvir.2011.02.017 
Leng, G. C., & Fowkes, F. G. (1992). The Edinburgh Claudication Questionnaire: an improved version of 
the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol, 45(10), 1101-
1109.  
Lijmer, J. G., Hunink, M. G., van den Dungen, J. J., Loonstra, J., & Smit, A. J. (1996). ROC analysis of 
noninvasive tests for peripheral arterial disease. Ultrasound Med Biol, 22(4), 391-398.  
Lowensteyn, I., Coupal, L., Zowall, H., & Grover, S. A. (2000). The cost-effectiveness of exercise training 
for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil, 20(3), 
147-155.  
Lundgren, F., Dahllof, A. G., Lundholm, K., Schersten, T., & Volkmann, R. (1989). Intermittent 
claudication--surgical reconstruction or physical training? A prospective randomized trial of 
treatment efficiency. Ann Surg, 209(3), 346-355.  
Mazari, F. A., Gulati, S., Rahman, M. N., Lee, H. L., Mehta, T. A., McCollum, P. T., & Chetter, I. C. (2010). 
Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and 
combined therapy in intermittent claudication. Ann Vasc Surg, 24(1), 69-79. 
doi:10.1016/j.avsg.2009.07.005 
McDermott, M. M., Ades, P., Guralnik, J. M., Dyer, A., Ferrucci, L., Liu, K., . . . Criqui, M. H. (2009). 
Treadmill exercise and resistance training in patients with peripheral arterial disease with and 
without intermittent claudication: a randomized controlled trial. Jama, 301(2), 165-174. 
doi:10.1001/jama.2008.962 
Milani, R. V., & Lavie, C. J. (2007). The role of exercise training in peripheral arterial disease. Vasc Med, 
12(4), 351-358. doi:10.1177/1358863x07083177 
Murphy, T. P., Cutlip, D. E., Regensteiner, J. G., Mohler, E. R., Cohen, D. J., Reynolds, M. R., . . . Hirsch, A. 
T. (2012). Supervised exercise versus primary stenting for claudication resulting from aortoiliac 
peripheral artery disease: six-month outcomes from the claudication: exercise versus 
endoluminal revascularization (CLEVER) study. Circulation, 125(1), 130-139. 
doi:10.1161/circulationaha.111.075770 
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. (2007). Inter-
Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg, 45 
Suppl S, S5-67. doi:10.1016/j.jvs.2006.12.037 
Parmenter, B. J., Dieberg, G., & Smart, N. A. (2015). Exercise training for management of peripheral 
arterial disease: a systematic review and meta-analysis. Sports Med, 45(2), 231-244. 
doi:10.1007/s40279-014-0261-z 
Parmenter, B. J., Raymond, J., Dinnen, P., Lusby, R. J., & Fiatarone Singh, M. A. (2013). High-intensity 
progressive resistance training improves flat-ground walking in older adults with symptomatic 
peripheral arterial disease. J Am Geriatr Soc, 61(11), 1964-1970. doi:10.1111/jgs.12500 
Perkins, J. M., Collin, J., Creasy, T. S., Fletcher, E. W., & Morris, P. J. (1996). Exercise training versus 
angioplasty for stable claudication. Long and medium term results of a prospective, randomised 
trial. Eur J Vasc Endovasc Surg, 11(4), 409-413.  
Reynolds, M. R., Apruzzese, P., Galper, B. Z., Murphy, T. P., Hirsch, A. T., Cutlip, D. E., . . . Cohen, D. J. 
(2014). Cost-effectiveness of supervised exercise, stenting, and optimal medical care for 
claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization 
(CLEVER) trial. J Am Heart Assoc, 3(6), e001233. doi:10.1161/jaha.114.001233 
Romiti, M., Albers, M., Brochado-Neto, F. C., Durazzo, A. E., Pereira, C. A., & De Luccia, N. (2008). Meta-
analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg, 47(5), 975-
981. doi:10.1016/j.jvs.2008.01.005 

Rose, G. A. (1962). The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. 
Bull World Health Organ, 27, 645-658.  
Schroder, F., Diehm, N., Kareem, S., Ames, M., Pira, A., Zwettler, U., . . . Diehm, C. (2006). A modified 
calculation of ankle-brachial pressure index is far more sensitive in the detection of peripheral 
arterial disease. J Vasc Surg, 44(3), 531-536. doi:10.1016/j.jvs.2006.05.016 
Spronk, S., Bosch, J. L., den Hoed, P. T., Veen, H. F., Pattynama, P. M., & Hunink, M. G. (2009). 
Intermittent claudication: clinical effectiveness of endovascular revascularization versus 
supervised hospital-based exercise training--randomized controlled trial. Radiology, 250(2), 586-
595. doi:10.1148/radiol.2501080607 
Takahara, M., Kaneto, H., Iida, O., Gorogawa, S., Katakami, N., Matsuoka, T. A., . . . Shimomura, I. (2010). 
The influence of glycemic control on the prognosis of Japanese patients undergoing 
percutaneous transluminal angioplasty for critical limb ischemia. Diabetes Care, 33(12), 2538-
2542. doi:10.2337/dc10-0939 
Van Schaardenburgh, M., Wohlwend, M., Rognmo, O., & Mattsson, E. (2017). Calf raise exercise 
increases walking performance in patients with intermittent claudication. J Vasc Surg, 65(5), 
1473-1482. doi:10.1016/j.jvs.2016.12.106 
Varu, V. N., Hogg, M. E., & Kibbe, M. R. (2010). Critical limb ischemia. J Vasc Surg, 51(1), 230-241. 
doi:10.1016/j.jvs.2009.08.073 
Willigendael, E. M., Teijink, J. A., Bartelink, M. L., Kuiken, B. W., Boiten, J., Moll, F. L., . . . Prins, M. H. 
(2004). Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc 
Surg, 40(6), 1158-1165. doi:10.1016/j.jvs.2004.08.049 
Zwierska, I., Walker, R. D., Choksy, S. A., Male, J. S., Pockley, A. G., & Saxton, J. M. (2005). Upper- vs 
lower-limb aerobic exercise rehabilitation in patients with symptomatic peripheral arterial 
disease: a randomized controlled trial. J Vasc Surg, 42(6), 1122-1130. 
doi:10.1016/j.jvs.2005.08.021